Meantime, co-treatment with 3-MA or Baf A1, or knockdown of ATG7 attenuated the two drug combination-induced increase of cleaved-caspase-3 and cleaved-PARP, and partly reduced the two drug combination-induced augmentation of sub G1 population and increase of caspase-3/7 activity in gefitinib-resistant NSCLC cells. This evidence concerns the gene CASP3 and non-small cell lung carcinoma.